From these observations, we concluded that in vivo, tumor progression and recurrence after primary treatment might benefit from a reduction in 53BP1 protein level, while, concomitantly, the expression of DNA-PKcs remains sustained. The gene discussed is TP53BP1; the disease is neoplasm.